Recent Price Movement and Market Context
On 4 Mar 2026, RPG Life Sciences Ltd opened with a gap down of -2.55%, continuing a three-day losing streak that has resulted in a cumulative decline of -6.8%. The stock touched an intraday low of Rs.1767.25, representing a -2.92% drop on the day and establishing a new 52-week low. This performance contrasts with the broader Sensex, which, despite opening 1,710.03 points lower, recovered by 297.78 points to trade at 78,826.60, down -1.76% overall.
The stock’s underperformance is further highlighted by its relative sector movement, lagging the Pharmaceuticals & Biotechnology sector by -0.71% on the day. Additionally, RPG Life Sciences is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
Long-Term Performance and Valuation Metrics
Over the last year, RPG Life Sciences has generated a negative return of -13.29%, significantly underperforming the Sensex’s positive 8.00% return and the BSE500’s 11.74% gain. The stock’s 52-week high was Rs.2715.90, indicating a substantial decline from its peak.
Despite this, the company maintains a Price to Book Value ratio of 5.5, which is considered fair relative to its peers’ historical valuations. The Return on Equity (ROE) stands at 19%, reflecting a reasonable level of profitability. Furthermore, the company’s profits have increased by 21.1% over the past year, resulting in a PEG ratio of 1.4, which suggests moderate valuation relative to earnings growth.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Financial Performance and Operational Indicators
RPG Life Sciences’ long-term growth has been modest, with net sales increasing at an annual rate of 11.84% and operating profit growing at 17.44% over the past five years. The company’s Return on Capital Employed (ROCE) for the half-year period is recorded at 26.37%, which is the lowest in recent assessments. Additionally, the Debtors Turnover Ratio for the half-year stands at 5.61 times, indicating a slower collection cycle compared to previous periods.
Quarterly earnings per share (EPS) have also declined, with the latest figure at Rs.13.38, marking the lowest quarterly EPS in recent times. These financial indicators collectively point to a period of subdued performance relative to historical benchmarks.
Shareholding and Market Perception
Despite the company’s size and presence in the Pharmaceuticals & Biotechnology sector, domestic mutual funds hold a minimal stake of only 0.15%. Given that domestic mutual funds typically conduct in-depth research and maintain significant positions in companies they favour, this small holding may reflect a cautious stance towards the stock’s current valuation or business outlook.
RPG Life Sciences’ Mojo Score currently stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold on 16 Jan 2026. The Market Cap Grade is rated at 3, indicating a mid-tier market capitalisation relative to other listed entities.
Considering RPG Life Sciences Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Debt Profile and Valuation Considerations
The company maintains a low average Debt to Equity ratio of 0, indicating a debt-free or negligible debt position. This conservative capital structure reduces financial risk and interest burden, which can be favourable in volatile market conditions.
While the stock’s recent price decline to Rs.1767.25 marks a significant low point, its valuation metrics such as Price to Book Value and ROE suggest that the stock is trading at a level consistent with its historical peer group valuations. The rise in profits by 21.1% over the past year contrasts with the negative stock returns, highlighting a divergence between earnings growth and market pricing.
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector has experienced mixed performance, with some indices such as the S&P BSE Realty also hitting 52-week lows on the same day. The Sensex remains below its 50-day moving average, although the 50DMA is still above the 200DMA, indicating some underlying market resilience despite short-term pressures.
RPG Life Sciences’ underperformance relative to both the sector and broader market indices over the past year underscores the challenges faced by the stock in maintaining investor confidence and price momentum.
Summary of Key Metrics
To summarise, RPG Life Sciences Ltd’s key data points as of 4 Mar 2026 include:
- New 52-week low price: Rs.1767.25
- One-year stock return: -13.29%
- Sensex one-year return: +8.00%
- Net sales growth (5 years CAGR): 11.84%
- Operating profit growth (5 years CAGR): 17.44%
- ROCE (half-year): 26.37%
- Debtors Turnover Ratio (half-year): 5.61 times
- EPS (quarterly): Rs.13.38
- Mojo Score: 37.0 (Sell grade)
- Market Cap Grade: 3
- Price to Book Value: 5.5
- ROE: 19%
- PEG Ratio: 1.4
- Debt to Equity Ratio: 0 (average)
These figures collectively illustrate the stock’s current valuation and performance landscape within the Pharmaceuticals & Biotechnology sector.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
